First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial.
Signal Transduct Target TherSep 1, 2026 (epub)
Yue Liu, Yanqiao Zhang, Rongbo Lin et al.
✦ AI-curated · Sources linked
In 30 seconds
The ANCHOR trial, a multicenter, prospective, randomized phase 3 study, compared first-line anlotinib with bevacizumab plus CapeOX in patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer. The study found that the median progression-free survival was 11.0 months for both treatment groups, with anlotinib failing to meet the noninferiority margin for PFS.
Key findings
- Median progression-free survival was 11.0 months for both anlotinib and bevacizumab groups.
- The hazard ratio for noninferiority was 1.00, indicating no significant difference in PFS.
- Grade ≥3 treatment-related adverse events occurred in 64.9% of the anlotinib group versus 44.8% in the bevacizumab group.
Why it matters
This study provides important insights into treatment options for metastatic colorectal cancer, highlighting that while anlotinib has similar efficacy to bevacizumab plus CapeOX, it is associated with higher toxicity, which may influence treatment decisions.